Phase 2
Completed N=154
Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease
Source: ClinicalTrials.gov NCT00359944 ↗Enrolled (actual)
154
Serious AEs
9.1%
Results posted
Jul 2013
Primary outcomePrimary: Total Score of Alzheimer's Disease Assessment Scale - Cognition Subscale (ADAS-COG)From Best Total Score (0) to Worst Total Score (70) — -1.3; -2.9; -1.5 units on a scale
Summary
The purpose of this study is to investigate efficacy and safety of different doses of AC-3933 in patients with mild to moderate Alzheimer's Disease.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Score of Alzheimer's Disease Assessment Scale - Cognition Subscale (ADAS-COG)From Best Total Score (0) to Worst Total Score (70) |
-1.3; -2.9; -1.5 | — |
| SECONDARY Clinicians Interview Based Impression of Change (CIBIC)-Plus |
4.1; 3.9; 3.9 | — |
| SECONDARY Disability Assessment for Dementia (DAD) |
-2.7; 4.0; 4.2 | — |
Eligibility Criteria
Inclusion Criteria
- Mild to moderate Alzheimer's Disease
- Male or female 55 years or older
- Living with caregiver
- Read, understand and speak English
Exclusion Criteria
- Need to drive during the study
- Treatment with acetylcholinesterase inhibitors or NMDA antagonist, such as Aricept or Namenda, within 2 weeks of check-up and during the study
- Frequent Smoker
- Frequent Consumer of Caffeine
Data sourced from ClinicalTrials.gov (NCT00359944). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.